|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL37 |
Gene summary for RPL37 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL37 | Gene ID | 6167 |
| Gene name | ribosomal protein L37 | |
| Gene Alias | L37 | |
| Cytomap | 5p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P61927 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6167 | RPL37 | GSM4909281 | Human | Breast | IDC | 7.82e-45 | -3.91e-01 | 0.21 |
| 6167 | RPL37 | GSM4909285 | Human | Breast | IDC | 6.66e-12 | -1.78e-01 | 0.21 |
| 6167 | RPL37 | GSM4909287 | Human | Breast | IDC | 4.50e-03 | 7.81e-02 | 0.2057 |
| 6167 | RPL37 | GSM4909291 | Human | Breast | IDC | 6.06e-18 | -3.36e-01 | 0.1753 |
| 6167 | RPL37 | GSM4909293 | Human | Breast | IDC | 7.05e-14 | 1.80e-01 | 0.1581 |
| 6167 | RPL37 | GSM4909294 | Human | Breast | IDC | 5.67e-09 | 1.29e-01 | 0.2022 |
| 6167 | RPL37 | GSM4909297 | Human | Breast | IDC | 8.53e-07 | -2.27e-01 | 0.1517 |
| 6167 | RPL37 | GSM4909298 | Human | Breast | IDC | 1.09e-06 | 1.35e-01 | 0.1551 |
| 6167 | RPL37 | GSM4909301 | Human | Breast | IDC | 3.37e-04 | -1.28e-01 | 0.1577 |
| 6167 | RPL37 | GSM4909302 | Human | Breast | IDC | 2.91e-07 | -2.19e-01 | 0.1545 |
| 6167 | RPL37 | GSM4909306 | Human | Breast | IDC | 4.95e-27 | -2.68e-01 | 0.1564 |
| 6167 | RPL37 | GSM4909307 | Human | Breast | IDC | 2.28e-08 | -1.47e-01 | 0.1569 |
| 6167 | RPL37 | GSM4909308 | Human | Breast | IDC | 1.05e-48 | -4.43e-01 | 0.158 |
| 6167 | RPL37 | GSM4909309 | Human | Breast | IDC | 7.14e-07 | -2.32e-01 | 0.0483 |
| 6167 | RPL37 | GSM4909312 | Human | Breast | IDC | 3.48e-04 | -1.32e-01 | 0.1552 |
| 6167 | RPL37 | GSM4909319 | Human | Breast | IDC | 5.74e-47 | -7.73e-01 | 0.1563 |
| 6167 | RPL37 | GSM4909321 | Human | Breast | IDC | 3.25e-11 | -2.26e-01 | 0.1559 |
| 6167 | RPL37 | brca1 | Human | Breast | Precancer | 1.17e-68 | -4.18e-01 | -0.0338 |
| 6167 | RPL37 | brca2 | Human | Breast | Precancer | 3.27e-22 | -2.11e-01 | -0.024 |
| 6167 | RPL37 | brca3 | Human | Breast | Precancer | 7.28e-16 | -1.70e-01 | -0.0263 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000218134 | Oral cavity | NEOLP | cytoplasmic translation | 102/2005 | 148/18723 | 3.70e-64 | 2.20e-60 | 102 |
| GO:190332033 | Oral cavity | NEOLP | regulation of protein modification by small protein conjugation or removal | 72/2005 | 242/18723 | 2.44e-16 | 1.61e-13 | 72 |
| GO:003139633 | Oral cavity | NEOLP | regulation of protein ubiquitination | 62/2005 | 210/18723 | 4.31e-14 | 1.60e-11 | 62 |
| GO:003139733 | Oral cavity | NEOLP | negative regulation of protein ubiquitination | 32/2005 | 83/18723 | 2.84e-11 | 3.92e-09 | 32 |
| GO:190332134 | Oral cavity | NEOLP | negative regulation of protein modification by small protein conjugation or removal | 33/2005 | 95/18723 | 3.57e-10 | 3.07e-08 | 33 |
| GO:005134833 | Oral cavity | NEOLP | negative regulation of transferase activity | 62/2005 | 268/18723 | 3.19e-09 | 1.91e-07 | 62 |
| GO:005144433 | Oral cavity | NEOLP | negative regulation of ubiquitin-protein transferase activity | 11/2005 | 19/18723 | 6.90e-07 | 1.93e-05 | 11 |
| GO:007233134 | Oral cavity | NEOLP | signal transduction by p53 class mediator | 37/2005 | 163/18723 | 7.22e-06 | 1.43e-04 | 37 |
| GO:190179833 | Oral cavity | NEOLP | positive regulation of signal transduction by p53 class mediator | 11/2005 | 25/18723 | 2.21e-05 | 3.60e-04 | 11 |
| GO:190179634 | Oral cavity | NEOLP | regulation of signal transduction by p53 class mediator | 24/2005 | 93/18723 | 3.18e-05 | 4.80e-04 | 24 |
| GO:190466633 | Oral cavity | NEOLP | regulation of ubiquitin protein ligase activity | 10/2005 | 23/18723 | 5.95e-05 | 7.97e-04 | 10 |
| GO:190466734 | Oral cavity | NEOLP | negative regulation of ubiquitin protein ligase activity | 7/2005 | 12/18723 | 7.77e-05 | 9.93e-04 | 7 |
| GO:005143833 | Oral cavity | NEOLP | regulation of ubiquitin-protein transferase activity | 15/2005 | 53/18723 | 3.19e-04 | 3.11e-03 | 15 |
| GO:000218118 | Prostate | BPH | cytoplasmic translation | 115/3107 | 148/18723 | 1.08e-60 | 6.68e-57 | 115 |
| GO:190332018 | Prostate | BPH | regulation of protein modification by small protein conjugation or removal | 90/3107 | 242/18723 | 7.37e-15 | 1.01e-12 | 90 |
| GO:007233118 | Prostate | BPH | signal transduction by p53 class mediator | 64/3107 | 163/18723 | 3.51e-12 | 2.82e-10 | 64 |
| GO:003139618 | Prostate | BPH | regulation of protein ubiquitination | 74/3107 | 210/18723 | 3.66e-11 | 2.39e-09 | 74 |
| GO:190179618 | Prostate | BPH | regulation of signal transduction by p53 class mediator | 38/3107 | 93/18723 | 2.31e-08 | 6.99e-07 | 38 |
| GO:190179818 | Prostate | BPH | positive regulation of signal transduction by p53 class mediator | 16/3107 | 25/18723 | 1.43e-07 | 3.36e-06 | 16 |
| GO:190332118 | Prostate | BPH | negative regulation of protein modification by small protein conjugation or removal | 37/3107 | 95/18723 | 1.54e-07 | 3.54e-06 | 37 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL37 | SNV | Missense_Mutation | c.113G>A | p.Gly38Asp | p.G38D | P61927 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-AG-3592-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RPL37 | SNV | Missense_Mutation | novel | c.118C>T | p.Pro40Ser | p.P40S | P61927 | protein_coding | deleterious(0.02) | possibly_damaging(0.828) | TCGA-A5-A1OH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | CR |
| RPL37 | SNV | Missense_Mutation | novel | c.164G>T | p.Arg55Ile | p.R55I | P61927 | protein_coding | deleterious(0) | possibly_damaging(0.808) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| RPL37 | SNV | Missense_Mutation | c.203N>T | p.Lys68Ile | p.K68I | P61927 | protein_coding | deleterious(0) | possibly_damaging(0.866) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RPL37 | SNV | Missense_Mutation | rs548862946 | c.265G>A | p.Ala89Thr | p.A89T | P61927 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL37 | SNV | Missense_Mutation | c.17N>T | p.Ser6Leu | p.S6L | P61927 | protein_coding | deleterious(0.02) | benign(0.376) | TCGA-64-5781-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| RPL37 | SNV | Missense_Mutation | novel | c.90G>C | p.Gln30His | p.Q30H | P61927 | protein_coding | deleterious(0.01) | benign(0.202) | TCGA-77-7465-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RPL37 | SNV | Missense_Mutation | novel | c.19N>A | p.Ser7Thr | p.S7T | P61927 | protein_coding | deleterious(0.01) | probably_damaging(0.938) | TCGA-CN-6013-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
| RPL37 | SNV | Missense_Mutation | c.152N>G | p.Ala51Gly | p.A51G | P61927 | protein_coding | tolerated(0.17) | benign(0.031) | TCGA-G9-6339-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | PD | |
| RPL37 | SNV | Missense_Mutation | c.25N>A | p.Gly9Arg | p.G9R | P61927 | protein_coding | deleterious(0.03) | benign(0.257) | TCGA-HU-A4G8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |